Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
Open Access
- 19 May 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 112 (12), 1874-1881
- https://doi.org/10.1038/bjc.2015.144
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal CancerThe New England Journal of Medicine, 2013
- Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients With KRAS Wild-Type Unresectable Colorectal Liver-Limited MetastasesJournal of Clinical Oncology, 2013
- Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant human lung and colorectal cancer cellsInternational Journal of Cancer, 2013
- Targeting the MAPK–RAS–RAF signaling pathway in cancer therapyEmerging Therapeutic Targets, 2012
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation StatusJournal of Clinical Oncology, 2011
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME StudyJournal of Clinical Oncology, 2010
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisThe Lancet Oncology, 2010
- Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivoBritish Journal of Haematology, 2010
- From basic research to clinical development of MEK1/2 inhibitors for cancer therapyJournal of Hematology & Oncology, 2010
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerThe New England Journal of Medicine, 2009